Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.

Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.

Uddin Zia; Maennle Diane; Russell Kimberly; Boltri John M

The Journal of Family Practice

2015

2015-07

Varying combinations of 3 measurable factors determine a patient's risk of progressing toward multiple myeloma and influence monitoring decisions. This review–and accompanying algorithm–can guide your approach. For monoclonal gammopathy of undetermined significance (MGUS) patients at low risk, repeat serum protein electrophoresis (SPE) in 6 months. If no significant elevation of

Humans; Male; Middle Aged; Prevalence; Disease Progression; Risk Assessment; Blood Protein Electrophoresis; Connectin/analysis; Monoclonal Gammopathy of Undetermined Significance/*diagnosis/epidemiology/therapy

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

E5–E12

7

64